Company intelligence / Profile preview

EngMab

Canton of Schwyz, Switzerlandgenmab.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EngMab was a Swiss biotech company founded in Schwyz in 2013 that developed T-cell bispecific antibodies targeting BCMA and CD3 for oncology indications, primarily multiple myeloma. Its lead asset EM801/Alnuctamab advanced into early clinical trials before the company was acquired by Celgene in late 2016. The technology aimed to redirect immune cells against cancer cells expressing BCMA. After acquisition, development continued under Celgene/Bristol Myers Squibb but recent major trials have been discontinued due to business priorities.

Therapeutic areas: Oncology
Modalities: Bispecific antibodies (T-cell bispecific antibodies, TCBs)Bispecific T-cell engagers (BiTEs)
Industry: Biotech

Drug pipeline

1 asset

EM901

Pre-clinical

Indications: Multiple myeloma, Hematological malignancies

Partnerships

No major external partnerships reported prior to acquisition; post-acquisition collaborations with bluebird bio on related BCMA programs noted at parent level.

Beyond the preview

Go deeper on EngMab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EngMab.

Explore the full profile